Trial Profile
To Evaluate the Safety and Metabolic Profile of Vyvanse for the Treatment of ADHD in Euthymic Adults With Bipolar I/II Disorder.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Lisdexamfetamine (Primary)
- Indications Attention-deficit hyperactivity disorder; Bipolar I disorders; Bipolar II disorders
- Focus Therapeutic Use
- 31 May 2012 Actual patient number added 45 according to ClinicalTrials.gov.
- 31 May 2012 Actual End Date added to 1 Jan 2012 as reported by ClinicalTrials.gov.
- 31 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.